Wednesday, November 13, 2013

Frustrated With Digital Experiences Correlates to Negative Brand Perception

Digital-PR Drag: People Are Increasingly Frustrated With Digital Experiences, and Walk Away With Negative Brand Perception, New EffectiveUI Study Finds.

Full article appears below.


November 13, 2013 -- Only 15 percent of people think technology—including mobile devices, smartphones and tablets—has made their life more complicated, according to a study conducted by Harris Interactive among more than 2,000 U.S. adults in October and commissioned by EffectiveUI. But while technology and quick access to information is making life easier, people also say that the digital experience is becoming more frustrating.
  • ·      93 percent of people have found themselves frustrated with the usability of a website, and, on average, are frustrated with websites 23 percent of the time.


  • ·      72 percent of mobile device owners have found themselves frustrated with the usability of a mobile app, on average 25 percent of the time.


This frustration has huge implications on a brand, as 87 percent of people say that a frustrating digital experience leads to at least a somewhat negative perception about that brand.
People say they want digital experiences to be easier. On average, people would do more of the following activities if they were easier:
  • Banking—Respondents said they would do nine percent more banking. Industry statistics point to growth specifically in the mobile market, with the percent of mobile banking users compared to PC banking users expected to more than double by 2017, according to a July 6, 2012 blog post by Susan Huynh of Forrester Research entitled: "The Data Digest: Mobile Banking's Massive Growth Is Supplementary To PC Banking."
  • Insurance—People say they would handle 13 percent more insurance needs. According to IBISWorld, the majority of insurance policies are initiated online, but most are still completed using an agent. With the industry as a whole estimated at $429 billion in the U.S., making it easier for consumers to conduct this business online could result in huge cost savings for providers.
  • Shopping—Respondents would do 12 percent more shopping online or via mobile. In a $225 billion market, as reported by Internet Retailer, this equates to a $27 billion opportunity for online retailers.
  • Reading—People say they would do seven percent more digital reading. BookStats reports that the eBook market was $1.54 billion in 2012, equating to a $108 million opportunity.
  • Television viewing—People would view nine percent more shows digitally. With IBISWorld estimating the market at $3 billion, this equates to an additional $270 million in revenue.

"The trouble with the current situation is that we, as digital professionals, consider ourselves to be tech savvy, but the people we are designing for don't see themselves that way," said Anthony Franco, president and co-founder of EffectiveUI, in a news release. "We have to start building experiences for the people we are meant to serve—to help solve problems not as engineers, but as empathetic human beings."

This survey was conducted online within the United States by Harris Interactive on behalf of EffectiveUI from October 28-30, 2013 among 2,016 adults ages 18 and older. This online survey is not based on a probability sample and therefore no estimate of theoretical sampling error can be calculated.

Tuesday, November 5, 2013

Clinical Trial News: UbiVac opens trial of next generation lung cancer vaccine


UbiVac, a clinical stage cancer immunotherapy company based in Portland, OR, announced the results of a Phase I clinical trial and the initiation of a Phase II clinical trial of its first-in-class autophagosome DRibble vaccine, DPV-001, in two presentations at the 15th World Conference for Lung Cancer, in Sydney. This novel vaccine approach may help the immune system recognize and fight remaining cancer cells.
Full press release below.
SOURCE: UbiVac
UbiVac Opens Trial of Next Generation Lung Cancer Vaccine
SYDNEY, Nov. 5, 2013 /PRNewswire/ -- UbiVac, a clinical stage cancer immunotherapy company based in Portland, OR, announced the results of a Phase I clinical trial and the initiation of a Phase II clinical trial of its first-in-class autophagosome DRibble vaccine, DPV-001, in two presentations at the 15th World Conference for Lung Cancer, in Sydney, from October 27-30. The multicenter, randomized Phase II clinical trial of DPV-001 is supported by a US$3.4 million National Cancer Institute (NCI) grant and will involve 48 individuals with definitively treated stage IIIA/B non-small cell lung cancer (NSCLC). A description of DPV-001, an "off-the-shelf vaccine," was presented by Dr. Helen Ross, Mayo Clinic Arizona, in an oral session (abstract #O-08.01). This next generation vaccine contains a system for targeting to dendritic cells, at least 9 cancer antigens prioritized by an NCI advisory panel and 5 toll-like receptor agonists to boost immunity. "Patients with locally advanced lung cancer still have a very high risk of cancer returning despite our most aggressive treatments," said Dr. Rachel Sanborn, the trial's principal investigator and the Co-Director of Thoracic Oncology, Providence Cancer Center, Portland, Oregon. "This novel vaccine approach may help the immune system recognize and fight remaining cancer cells." In a presentation of the Phase 1 trial in patients with Stage IV NSCLC, the authors reported that immune responses were detected in a majority of the evaluable patients (abstract # P-3.11-032).
"UbiVac is excited to pioneer this first-in-class vaccine technology to patients with NSCLC," said Dr. Hong-Ming Hu, inventor of autophagosome DRibble technology, Co-founder and CSO of UbiVac. "In addition to lung cancer, UbiVac is actively pursuing the application of this technology, with our partners and collaborators, for the treatment of head and neck, hepatocellular, prostate, colon and breast cancer."
UbiVac, spun-out from the Providence Health System in 2005, recently was judged by Oregon CEOs as the top "Presenting Company" at the Oregon Bioscience Association annual meeting has three vaccine platform technologies under development: DRibbles, a nanotechnology platform and a disabled cytomegalovirus (CMV) vector platform.
The ongoing activities reported in this release are supported by the NCI of the National Institutes of Health under Award Numbers R44CA121612 and U43CA165048. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NCI or the National Institutes of Health.
SOURCE: UbiVac
CONTACT: UbiVac, Bernard Fox, 503-922-1160, PR@UbiVac.com


Saturday, November 2, 2013

NaNoWriMo Nov 1-Nov 30, Who's In?

What is NaNoWriMo?

NaNoWriMo is an annual (November) novel writing project that brings together professional and amateur writers from all over the world. Check out the website at www.nanowrimo.org.

How It Works

During NaNoWriMo, you write 50,000 words in the 30 days of November. The challenge may be hard, but the logistics are not! Here, let us guide you through ‘em.
1. Sign up for our website with that big, blue “Sign Up!” button on the homepage. You’ll get an email validation link a few minutes later.
2. As part of the sign-up process, you’ll choose a home region for in-person events near you. This is totally optional, but we think it’s a pretty awesome part of the NaNo experience.
3. Our user dashboard will usher you through the rest of your account set-up stuff. Click on the grayed-out badges to fill out your profile, say hello in our forums, and add writing buddies.
4. On October 1, you’ll be able to add information about your upcoming novel to your profile. Giving your work a title or brief synopsis gets you 225% more pumped for November. It’s a fact.
5. You can also use October to read past author pep talks, grab participant web badges, meet folks in the forums, and learn more about our nonprofit.
6. At midnight on November 1, start writing. Work on your manuscript using any method where you can track your word count. Word-processing program, notebook, typewriter, stone slab: they all work.
7. Update your word count whenever you can. Some like every day; others prefer a few times a week. No matter when, you can do it in that word-count update menu at the top of every page on our site.
8. Stay motivated with pep talks (we’ll send them to your on-site inbox and your email), forum chatter, and in-person events in your region. There’s also a big world of NaNo out there in social media: find us on Facebook, Twitter, Tumblr, YouTube, and Pinterest.
9. Starting on November 25, you can validate your novel to win. If it’s over 50,000 words, paste the text into the word-count validator. A few robotic calculations later, we’ll declare you an official NaNoWriMo winner! From there, you’ll be able to collect a few prime novelist goodies.
10. If you enjoy your NaNo experience, please donate to support our mission. We believe in making this a more creative world, and we’d love your help getting there. (Here’s more about why others donate, as well as additional ways to give.)
I'm participating this year! If anyone else is, and is willing to link up as a Writing Buddy on the  NaNoWriMo website, please tweet me back! @debhealthcare
Let the writing begin!


 

Friday, November 1, 2013

Navigating the digital future: Apple and Google top most innovative list


Navigating the digital future: Apple and Google top most innovative list again in Booz & Company R&D Study. Report explores which digital innovation tools really make a difference. Despite the sustained overall increase in R&D budgets over the last decade, this year's findings show once again that higher spending doesn't guarantee bigger payoffs

FULL ARTICLE APPEARS BELOW
SOURCE: Bulldog Reporter, www.bulldogreporter.com
DATE: November 1, 2013
Navigating the Digital Future: Apple and Google Top Most Innovative List Again In Booz & Company R&D Study—Report Explores Which Digital Innovation Tools Really Make a Difference.  
Yearly R&D spending among the world's 1,000 largest public corporate R&D spenders has hit a record high of $638 billion, according to global management consulting firm Booz & Company in its ninth annual Global Innovation 1000 study. However, despite the sustained overall increase in R&D budgets over the last decade, this year's findings show once again that higher spending doesn't guarantee bigger payoffs. Indeed, the 10 most innovative companies our study identified this year financially outperformed the world's top 10 spenders, despite actually spending significantly less on R&D. Additionally, the study shows that companies are spending 8.1 percent of their R&D budgets on digital tools to enable their innovation process—either to boost productivity or to improve their ability to gain better insight into customer needs.
10 Most Innovative Companies: Apple and Google Reign; Tesla Debuts
Apple and Google took top honors for the fourth consecutive year, but there were some noticeable shake-ups on the latest Global Innovation 1000 study's survey ranking of the 10 most innovative companies. Samsung displaced 3M from the number three spot for the first time, capping its steady rise in the rankings, and Amazon also made a significant move up, jumping six spots into fourth place. New to the list this year was Tesla, making its debut in the number nine slot, and Facebook returned at number 10 after a hiatus last year.
10 Most Innovative Companies Outperform Top R&D Spenders—Again
Google and Sony joined the top 20 R&D spenders list this year, at number 12 and number 20, respectively. The vast majority of the companies on the list—18 in total—were from the software & Internet, healthcare and automotive industries, industries that, combined, accounted for nearly three quarters of worldwide R&D spending growth in 2013. "The 22 percent increase in R&D spending among software and internet companies is likely driven by an increasing demand for digital products and services, creating more opportunities for cutting edge innovation," said Richard Holman, a partner at Booz & Company and coauthor of the study, in a news release.
Higher R&D spending is no guarantee of better financial performance. This year's 10 most innovative companies outperformed the top 10 spenders on both five-year revenue and market-cap growth averages.
"For the ninth straight year, our research has demonstrated that there is no correlation between how much you spend and how well you perform over the long term," said Barry Jaruzelski, senior partner at Booz & Company and global leader of the Engineered Products & Services practice, in the release. "It has been proven time and time again that you can't buy your way to the top. When it comes to innovation, how you spend is much more important than how much you spend."
Today's Digital Innovation Tools: Must-Have Enablers and Much-Needed Experimentation
Each year, the Global Innovation 1000 study examines trends in how companies innovate. This year's study explores how companies are driving innovation using digital tools, including (1) productivity enablers such as rapid prototyping/3D printing (found to be the most effective tool for the ideation phase of the innovation process), simulation tools, and project management tools, as well as (2) market and customer insight enablers, such as discussion platforms, monitoring tools, and usage monitoring sensors. The global R&D executives surveyed as part of the study said their companies allocated an average of 8.1 percent of the R&D budget to digital tools, which suggests spending of about $52 billion when extrapolated to the top 1,000 R&D spenders. The study also found that respondents whose companies made significant use of these digital enablers were much more likely to report that they outperformed competitors financially than were those who employed enablers more moderately.
"There are a whole slew of digital tools available today. Productivity enablers like computer-aided design and project management are now mature and are must-haves for any competitive innovator. More recent tools, such as big data, usage sensors, and social voting are focused on generating deep customer insights to help create more compelling products. While these are still pretty new, they are beginning to prove their value in multiple industries," said John Loehr, partner at Booz & Company and global leader of the firm's Innovation practice, in the release. "It's still a risk to invest in them, but one everyone will have to take to stay at the forefront of innovation."
Other key findings from this year's Global Innovation 1000 study:
•  R&D spending in 2013 rose by 5.8 percent from the previous year, signaling a return to the long-term growth trend after two years of faster growth following the recession.
•  Regionally, companies headquartered in China increased R&D spending by 35.8 percent and added 50 percent more companies to the Global Innovation 1000 from 2012 to 2013—both the highest percentage increases of any major country. Although China's spending growth rate remains significantly higher than that of any other region, this is the second-lowest increase for the country in the last five years.
•  Ninety percent of R&D spending worldwide in 2013 was from companies headquartered in North America, Europe, and Japan.
•  R&D spending in Europe grew by 4.5 percent despite the region's ongoing economic pressures, slower than the global average.
•  Japan's R&D spending decreased by 3.6 percent in 2013, marking the first time since the 2008-09 recession that any major economy reported a decrease in R&D spending.
•  Computers & electronics, healthcare, and automotive remained the three largest industries in terms of total R&D spend in 2013, representing 65 percent of the global total.
For full copy of the study, visit the link: 
http://www.booz.com/global/home/what-we-think/global-innovation-1000?utm_source=VanityURL&utm_content=innovation1000&utm_medium=redirect&utm_campaign=inov1000